Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.

Previous studies suggest that protective immunity against Schistosoma haematobium is primarily stimulated by antigens from dying worms. Praziquantel treatment kills adult worms, boosting antigen exposure and protective antibody levels. Current schistosomiasis control efforts use repeated mass drug a...

Full description

Saved in:
Bibliographic Details
Main Authors: Kate M Mitchell, Francisca Mutapi, Takafira Mduluza, Nicholas Midzi, Nicholas J Savill, Mark E J Woolhouse
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0003059
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849469134988902400
author Kate M Mitchell
Francisca Mutapi
Takafira Mduluza
Nicholas Midzi
Nicholas J Savill
Mark E J Woolhouse
author_facet Kate M Mitchell
Francisca Mutapi
Takafira Mduluza
Nicholas Midzi
Nicholas J Savill
Mark E J Woolhouse
author_sort Kate M Mitchell
collection DOAJ
description Previous studies suggest that protective immunity against Schistosoma haematobium is primarily stimulated by antigens from dying worms. Praziquantel treatment kills adult worms, boosting antigen exposure and protective antibody levels. Current schistosomiasis control efforts use repeated mass drug administration (MDA) of praziquantel to reduce morbidity, and may also reduce transmission. The long-term impact of MDA upon protective immunity, and subsequent effects on infection dynamics, are not known. A stochastic individual-based model describing levels of S. haematobium worm burden, egg output and protective parasite-specific antibody, which has previously been fitted to cross-sectional and short-term post-treatment egg count and antibody patterns, was used to predict dynamics of measured egg output and antibody during and after a 5-year MDA campaign. Different treatment schedules based on current World Health Organisation recommendations as well as different assumptions about reductions in transmission were investigated. We found that antibody levels were initially boosted by MDA, but declined below pre-intervention levels during or after MDA if protective immunity was short-lived. Following cessation of MDA, our models predicted that measured egg counts could sometimes overshoot pre-intervention levels, even if MDA had had no effect on transmission. With no reduction in transmission, this overshoot occurred if protective immunity was short-lived. This implies that disease burden may temporarily increase following discontinuation of treatment, even in the absence of any reduction in the overall transmission rate. If MDA was additionally assumed to reduce transmission, a larger overshoot was seen across a wide range of parameter combinations, including those with longer-lived protective immunity. MDA may reduce population levels of immunity to urogenital schistosomiasis in the long-term (3-10 years), particularly if transmission is reduced. If MDA is stopped while S. haematobium is still being transmitted, large rebounds (up to a doubling) in egg counts could occur.
format Article
id doaj-art-9aa3d121d3cc43de9b382414d4e137eb
institution Kabale University
issn 1935-2727
1935-2735
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj-art-9aa3d121d3cc43de9b382414d4e137eb2025-08-20T03:25:37ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352014-01-0187e305910.1371/journal.pntd.0003059Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.Kate M MitchellFrancisca MutapiTakafira MduluzaNicholas MidziNicholas J SavillMark E J WoolhousePrevious studies suggest that protective immunity against Schistosoma haematobium is primarily stimulated by antigens from dying worms. Praziquantel treatment kills adult worms, boosting antigen exposure and protective antibody levels. Current schistosomiasis control efforts use repeated mass drug administration (MDA) of praziquantel to reduce morbidity, and may also reduce transmission. The long-term impact of MDA upon protective immunity, and subsequent effects on infection dynamics, are not known. A stochastic individual-based model describing levels of S. haematobium worm burden, egg output and protective parasite-specific antibody, which has previously been fitted to cross-sectional and short-term post-treatment egg count and antibody patterns, was used to predict dynamics of measured egg output and antibody during and after a 5-year MDA campaign. Different treatment schedules based on current World Health Organisation recommendations as well as different assumptions about reductions in transmission were investigated. We found that antibody levels were initially boosted by MDA, but declined below pre-intervention levels during or after MDA if protective immunity was short-lived. Following cessation of MDA, our models predicted that measured egg counts could sometimes overshoot pre-intervention levels, even if MDA had had no effect on transmission. With no reduction in transmission, this overshoot occurred if protective immunity was short-lived. This implies that disease burden may temporarily increase following discontinuation of treatment, even in the absence of any reduction in the overall transmission rate. If MDA was additionally assumed to reduce transmission, a larger overshoot was seen across a wide range of parameter combinations, including those with longer-lived protective immunity. MDA may reduce population levels of immunity to urogenital schistosomiasis in the long-term (3-10 years), particularly if transmission is reduced. If MDA is stopped while S. haematobium is still being transmitted, large rebounds (up to a doubling) in egg counts could occur.https://doi.org/10.1371/journal.pntd.0003059
spellingShingle Kate M Mitchell
Francisca Mutapi
Takafira Mduluza
Nicholas Midzi
Nicholas J Savill
Mark E J Woolhouse
Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
PLoS Neglected Tropical Diseases
title Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
title_full Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
title_fullStr Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
title_full_unstemmed Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
title_short Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
title_sort predicted impact of mass drug administration on the development of protective immunity against schistosoma haematobium
url https://doi.org/10.1371/journal.pntd.0003059
work_keys_str_mv AT katemmitchell predictedimpactofmassdrugadministrationonthedevelopmentofprotectiveimmunityagainstschistosomahaematobium
AT franciscamutapi predictedimpactofmassdrugadministrationonthedevelopmentofprotectiveimmunityagainstschistosomahaematobium
AT takafiramduluza predictedimpactofmassdrugadministrationonthedevelopmentofprotectiveimmunityagainstschistosomahaematobium
AT nicholasmidzi predictedimpactofmassdrugadministrationonthedevelopmentofprotectiveimmunityagainstschistosomahaematobium
AT nicholasjsavill predictedimpactofmassdrugadministrationonthedevelopmentofprotectiveimmunityagainstschistosomahaematobium
AT markejwoolhouse predictedimpactofmassdrugadministrationonthedevelopmentofprotectiveimmunityagainstschistosomahaematobium